In clinical settings, inhibition of IL-1β through specific agonists or through IFN-β therapy is useful in limiting the development and progression of autoimmune and inflammation-mediated diseases, including rheumatoid arthritis and multiple sclerosis (18, 33, 57). This evidence concerns the gene IFNB1 and Autoimmunity.